Intestinal Permeability in Non-alcoholic Fatty LIVER Disease: The Gut-liver Axis

被引:28
|
作者
Scarpellini, E. [1 ]
Lupo, M. [2 ]
Iegri, C. [2 ]
Gasbarrini, A. [3 ]
De Santis, A. [2 ]
Tack, J. [1 ]
机构
[1] KULeuven, TARGID, Leuven, Belgium
[2] Sapienza Univ Rome, Umberto I Univ Hosp, Div Gastroenterol, Rome, Italy
[3] Gemelli Univ Hosp, Internal Med & Gastroenterol Div, Rome, Italy
关键词
Intestinal permeability; zonulin-1; claudin; nafld; nash; lipopolysaccharide;
D O I
10.2174/1574887109666141216104334
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The gut-liver axis model has helped to explain the liver steatosis (NAFLD) and steatohepatitis (NASH) etiopathogenesis. The discovery of a key role for an altered intestinal permeability (IP) in this pathophysioligcal framework has closed the link between gut lumen antigenic/toxic substances and systemic and liver inflammation in NAFLD and obesity, metabolic syndrome. Recent evidence from the literature show how IP can be modulated by several non-pharmacological and pharmacological agents and be the target for future preventive and curative treatment of NAFLD and NASH. In this review we describe the concept of IP, its ultrastructural basis, its role in the NALFD pathophysiology and emerging evidence on non-pharmacological and pharmacological agents able to favourably modulate it.
引用
收藏
页码:141 / 147
页数:7
相关论文
共 50 条
  • [1] Gut-Liver Axis Derangement in Non-Alcoholic Fatty Liver Disease
    Poeta, Marco
    Pierri, Luca
    Vajro, Pietro
    CHILDREN-BASEL, 2017, 4 (08):
  • [2] Deciphering the Gut-Liver Axis: A Comprehensive Scientific Review of Non-Alcoholic Fatty Liver Disease
    Singh, Samradhi
    Kriti, Mona
    Catanzaro, Roberto
    Marotta, Francesco
    Malvi, Mustafa
    Jain, Ajay
    Verma, Vinod
    Nagpal, Ravinder
    Tiwari, Rajnarayan
    Kumar, Manoj
    LIVERS, 2024, 4 (03): : 435 - 454
  • [3] Gut-Liver Axis in Alcoholic Liver Disease
    Szabo, Gyongyi
    GASTROENTEROLOGY, 2015, 148 (01) : 30 - 36
  • [4] Amelioratory Effect of Resistant Starch on Non-alcoholic Fatty Liver Disease via the Gut-Liver Axis
    Zhu, Weifeng
    Zhou, Ying
    Tsao, Rong
    Dong, Huanhuan
    Zhang, Hua
    FRONTIERS IN NUTRITION, 2022, 9
  • [5] Intestinal permeability is increased in children with non-alcoholic fatty liver disease, and correlates with liver disease severity
    Giorgio, Valentina
    Miele, Luca
    Principessa, Luigi
    Ferretti, Francesca
    Villa, Maria Pia
    Negro, Valentina
    Grieco, Antonio
    Alisi, Anna
    Nobili, Valerio
    DIGESTIVE AND LIVER DISEASE, 2014, 46 (06) : 556 - 560
  • [6] The liver X receptor: A master regulator of the gut-liver axis and a target for non alcoholic fatty liver disease
    Ducheix, Simon
    Montagner, Alexandra
    Theodorou, Vassilia
    Ferrier, Laurent
    Guillou, Herve
    BIOCHEMICAL PHARMACOLOGY, 2013, 86 (01) : 96 - 105
  • [7] The role of the gut-liver axis in modulating non-alcoholic fatty liver disease through dietary patterns and microecological agents
    Fang, Yucheng
    Fang, Ziyang
    Li, Ziwei
    Yu, Run
    Zhang, Haimeng
    Wang, Qinwen
    Cheng, Xiangrong
    Le, Guowei
    Wu, Guoqing
    FOOD BIOSCIENCE, 2023, 56
  • [8] Partially hydrolyzed guar gum attenuates non-alcoholic fatty liver disease in mice through the gut-liver axis
    Takayama, Shun
    Katada, Kazuhiro
    Takagi, Tomohisa
    Iida, Takaya
    Ueda, Tomohiro
    Mizushima, Katsura
    Higashimura, Yasuki
    Morita, Mayuko
    Okayama, Tetsuya
    Kamada, Kazuhiro
    Uchiyama, Kazuhiko
    Handa, Osamu
    Ishikawa, Takeshi
    Yasukawa, Zenta
    Okubo, Tsutomu
    Itoh, Yoshito
    Naito, Yuji
    WORLD JOURNAL OF GASTROENTEROLOGY, 2021, 27 (18) : 2160 - 2176
  • [9] Research Progress on the Therapeutic Effect of Polysaccharides on Non-Alcoholic Fatty Liver Disease through the Regulation of the Gut-Liver Axis
    Chen, Xiang
    Liu, Menghan
    Tang, Jun
    Wang, Ning
    Feng, Yibin
    Ma, Haotian
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (19)
  • [10] Targeting the Gut Microbiota for the Treatment of Non-Alcoholic Fatty Liver Disease
    Mouzaki, Marialena
    Bandsma, Robert
    CURRENT DRUG TARGETS, 2015, 16 (12) : 1324 - 1331